Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Science Advisor

Lihui Bai

Goodwin Procter

main

Bai Lihui

Goodwin Science Advisor Lihui Bai from Washington, practices in the Litigation Department with an emphasis on IP litigation.

Lihui Bai

Areas of Practice

PROFESSIONAL EXPERIENCE

Credentials

Education

PhDChemistry2022

BSChemistry2016

Publications

Related Content

FDA Approves First Gene Therapy to Treat Children with Metachromatic Leukodystrophy

FDA Approves First Cellular Therapy for Treatment of Unresectable or Metastatic Melanoma

PTAB Issues Final Written Decisions Finding Claims of Aflibercept-related Patents Invalid

Recent Biosimilar Approvals

Biogen Announces FDA Approval of TOFIDENCE, a Tocilizumab Biosimilar Referencing ACTEMRA

PTAB Issues Final Written Decisions Finding Claims of Tocilizumab-related Patents Invalid

Aflibercept IPR Updates

Samsung Bioepis Files Four IPR Petitions on Alexion Eculizumab Patents and One IPR Petition on a Janssen Ustekinumab Patent

Intellectual Property

Patent Litigation

Intellectual Property Litigation